Shai_Halud / Shutterstock.com
Drugs company Horizon Pharma has agreed to settle a patent dispute centring on a proposed generic version of its anti-inflammatory drug Pennsaid (diclofenac sodium topical solution).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Horizon Pharma, patent, licensing, Taro Pharmaceutical Industries, Pennsaid, patent licensing